Abstract 246P
Background
To study the main causes of neglect of advanced cervical cancer (CC) in Uzbekistan based on the results of a survey of advanced stage cervical cancer patients. The questionnaire was analyzed in 3 directions: “patient delay”, “doctor delay”, “delay of treatment”.
Methods
200 patients with advanced cervical cancer were included in the analysis, including: IIA-B stage-17%; IIIA-B stage 80%; IVA stage - 3%. Descriptive analyses were provided with the WHO questionnaire, adopted for local use, which should explore the possible barriers of early detection of cervical cancer.
Results
In the questionnaire analysis, the following results were obtained in the direction of “doctor delay”: 1. Which doctor did you talk about the symptoms of the disease? General practioner - 8%, gynecologist - 90%, private doctor - 2%; 2. Prior to the establishment of diagnosis contacted doctor: once - 22%, twice - 29%, 3 times and more - 49%. 3. How many times did you have a doctor before starting chemotherapy: Never - 86%, 3 or more times 14%. 4. Some aspects of the treatment surprised patients, no one warned: yes-56%, no-54%; I can easily ask doctor about the disease: Yes-45%, no-55%. 5. Appeal to the doctors before the establishment of diagnosis: twice - 29%, 3 and more time - 49%; To which specialist did you first tell about the symptoms of the disease: Physician - 97%, nurse - 2%, healer - 1%. 6. How many times have been in doctor with relatives: Never -37%; once - 19%; twice - 24%; 3 and more times - 20%. 7. Where you underwent the necessary examinations: State clinic - 70%; private clinic - 30%.
Conclusions
The main reasons for the neglect of cervical cancer in the direction of “doctor delay” are: Weak awareness of general practitioners; Unsatisfactory in forming patients about the severity of the disease, inability to enter the patient's trust; Absence or low level of psychological support of patients; Problems of timely referral of patients to an oncologist; Problems of deontology in the chain: doctor-diagnosis-patient. Elimination of the above-mentioned main causes will lower the incidence and mortality from cervical cancer and improve treatment outcomes, preventing disability of women.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nargiza Zakhirova.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract